A Multicenter, Open Label Study to Assess the Effect of Trastuzumab + Whole Brain Radiotherapy (WBRT) on Brain Metastases From HER-2 Positive Breast Cancer (bHERt-2).

Trial Profile

A Multicenter, Open Label Study to Assess the Effect of Trastuzumab + Whole Brain Radiotherapy (WBRT) on Brain Metastases From HER-2 Positive Breast Cancer (bHERt-2).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Brain metastases; Breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Planned End Date changed from 1 Jun 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top